Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in San Francisco MILAN and NEW YORK , Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is
MILAN and NEW YORK , Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy - U.S. meeting “Cross-Border Investments and Strategies in
Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2 MILAN and NEW YORK , Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia
MILAN , Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial MILAN, Italy and NEW YORK , Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of
MILAN, Italy and NEW YORK , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A . (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK , July 28, 2023 (GLOBE NEWSWIRE) -- Genenta
MILAN, Italy and NEW YORK , June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the
Prof. Luigi Naldini will present updates on the efficacy of Temferon in pre-clinical solid tumor models and preliminary clinical biological data confirming in patients MILAN, Italy and NEW YORK , May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini , Ph.D., M.D., co-founder and Executive Scientific Board
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025 Net exchange rate gain of €2.3 million Tax credit of €6.4 million MILAN , Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A .
